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Cytidine triphosphate synthetase (CTPS) catalyzes the rate-
limiting step in the de novo synthesis of CTP, and both the yeast
and human enzymes have been reported to be regulated by pro-
tein kinase A or protein kinase C phosphorylation. Here, we
provide evidence that stimulationor inhibitionof protein kinase
A and protein kinase C does not alter the phosphorylation of
endogenous human CTPS1 in human embryonic kidney 293
cells under the conditions tested. Unexpectedly, we found that
low serumconditions increasedphosphorylation of endogenous
CTPS1 and this phosphorylation was inhibited by the glycogen
synthase kinase 3 (GSK3) inhibitor indirubin-3-monoxime and
GSK3 short interfering RNAs, demonstrating the involvement
of GSK3 in phosphorylation of endogenous humanCTPS1. Sep-
arating tryptic peptides from [32P]orthophosphate-labeled cells
and analyzing the phosphopeptides bymass spectrometry iden-
tified Ser-574 and Ser-575 as phosphorylated residues. Muta-
tion of Ser-571 demonstrated that Ser-571 was the major site
phosphorylated byGSK3 in intact human embryonic kidney 293
cells by GSK3 in vitro. Furthermore, mutation of Ser-575 pre-
vented the phosphorylation of Ser-571, suggesting that phos-
phorylation of Ser-575 was necessary for priming the GSK3
phosphorylation of Ser-571. Low serum was found to decrease
CTPS1 activity, and incubation with the GSK3 inhibitor indiru-
bin-3-monoxime protected against this decrease in activity.
Incubation with an alkaline phosphatase increased CTPS1
activity in a time-dependent manner, demonstrating that phos-
phorylation inhibits CTPS1 activity. This is the first study to
investigate the phosphorylation and regulation of human
CTPS1 in human cells and suggests that GSK3 is a novel regula-
tor of CTPS activity.
Pyrimidine nucleotides have been known for decades to be
essential components of cells. Most recently the effects of
nucleotides have been revisited and were shown to regulate
apoptosome formation by binding to cytochrome c, and consti-
tutively high levels of nucleotides were shown to inhibit the cell
cycle and the response to DNA damage (1, 2). Of all the nucle-
otides, the cellular concentration of cytidine triphosphate
(CTP) is the lowest, suggesting that control of CTP synthesis is
tightly regulated (3). CTP is important in DNA/RNA synthesis,
phospholipid synthesis, and protein sialylation, which are
needed for cell proliferation and cell size expansion. CTP levels
are elevated during S phase of the cell cycle, and rapidly prolif-
erating cells maintain a higher basal concentration of CTP and
dCTP (4–10). Cytidine nucleotide levels were also found to be
elevated in a variety of tumors and elevated, albeit to a lesser
degree, in normal proliferating cells (11, 12). Primary human
lymphocytes demonstrate a dramatic increase in CTP levels
following mitogenic stimulation, demonstrating the impor-
tance of CTP synthesis in response to mitogens (12).
Cytidine triphosphate synthetase (CTPS2; EC 6.3.4.2) cata-
lyzes the rate-limiting step in the de novo formation of CTP; in
mammalian cells CTPS catalyzes the amination of UTP to form
CTP,with glutamine serving as the amine donor andATPbeing
hydrolyzed during the process. CTPS activity is feedback-in-
hibited byCTP, andwith glutamine as a substrateCTPS activity
ismarkedly enhanced byGTP. Inmammals there are twoCTPS
isozymes that share 74% amino acid identity (13). In the yeast
Saccharomyces cerevisiae there are also two isoforms of CTPS,
URA7 and URA8, corresponding to the mammalian enzymes
CTPS1 and CTPS2, respectively. Investigation into how CTPS
is regulated, primarily in bacteria and yeast, has uncovered two
major forms of regulation, regulation by metabolites and phos-
phorylation. The unique ability of CTPS to bind four nucleo-
tides (UTP, ATP,GTP, andCTP) and the amino acid glutamine
makes CTPS sensitive to the metabolite levels of four nucleo-
tides and glutamine in cells, providing exquisite metabolic con-
trol of CTPS.
Regulation of yeast CTPS by phosphorylationwas discovered
by Carman and co-workers (14), who showed that yeast CTPS1
(URA7) was phosphorylated in vitro on multiple sites by pro-
tein kinase C (Ser-36, Ser-330, Ser-354, and Ser-454).Mutation
of potential phosphorylation sites demonstrated that Ser-330
was amajor site of protein kinaseCphosphorylation (14). Addi-
tionally, this same group identified Ser-424 as an in vitro pro-
tein kinase A phosphorylation site (15). The S424A mutant
showed decreased CTPS activity and greater sensitivity to CTP
feedback inhibition (15). Recently this same group also showed
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that human CTPS1 expressed in yeast was phosphorylated by
protein kinase A (16). However, sequence alignments of the
yeast CTPS1 phosphorylation sites with mouse and human
CTPS1 indicate that only two of the phosphorylation sites iden-
tified in yeast CTPS1 (URA7) are conserved in humans (supple-
mental Fig. S1), suggesting that human CTPS1 in human cells
may be phosphorylated on different sites than URA7.
Despite the importance of CTP in processes such as phos-
pholipid synthesis and protein sialylation, little is known about
the regulation of humanCTPS1. The objective of this studywas
to investigate the phosphorylation and regulation of mamma-
lian CTPS1 expressed inmammalian cells. Endogenous human
CTPS1 was found to be phosphorylated by glycogen synthase
kinase 3 (GSK3) in response to low serum, and several phos-
phorylation sites in human CTPS1 were mapped to the car-
boxyl terminus, including the site for GSK3 phosphorylation.
Phosphorylation of endogenous human CTPS1 was found to
inhibit CTPS1 activity, and inhibition of GSK3 restored the low
serum decrease in CTPS1 activity. Thus, these studies suggest
that human CTPS1 expressed in human cells is regulated by
GSK3 phosphorylation of CTPS1, a carboxyl terminal residue
not found in the yeast enzyme.
EXPERIMENTAL PROCEDURES
Cell Culture—Human embryonic kidney (HEK) 293 cells
purchased from the University of North Carolina Tissue Culture
facility were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) (high glucose) supplemented with 100 units/ml penicil-
lin, 100 mg/ml streptomycin, and 10% heat-inactivated fetal
bovine serum (FBS) in an atmosphere of 5% CO2.
Plasmid Construction and Site-directed Mutagenesis—Full-
length cDNA containing human CTPS1 was purchased from
Invitrogen (IMAGE clone ID 3355881). A carboxyl-terminal
FLAG sequence was introduced after insertion of human
CTPS1 into pCDNA 4 myc/his using the compatible cohesive
ends EagI&NotI and XhoI. Briefly, the CTPS1 IMAGE clone
was digested with EagI and XhoI and ligated into pCDNA4
digested with NotI and XhoI. Introduction of the carboxyl-ter-
minal FLAG sequence was done by first amplifying a carboxyl-
terminal section of CTPS1 with the sense primer 5-CACGA-
AGCTTGGCAGAAGC-3 (HindIII site is underlined) and
antisense primer 5-GACTCGAGCGCTTGTCGTCATCGT-
CTTTGTAATCCGCGTCATGATTTATTGATGG-3 (XhoI
site is underlined, FLAG sequence (DYKDDDDK) is boldface,
and mutation of stop codon to alanine is italicized and under-
lined) and finally ligating the carboxyl-terminal-amplified sec-
tion back into the pCDNA4 CTPS1 using HindIII and XhoI
restriction sites. A Kozak sequence (GCCACC) was added
upstream of the start codon (ATG) by amplifying an amino-
terminal fragment of CTPS1 with the sense primer 5-CGCG-
GCCGCGCCACCATGAAGTACATTCTG-3 (NotI site is
underlined and start codon is boldface) and antisense primer
5-CGGATCCGCGTCATGATTTATTGATGG-3, digesting
the amplified amino-terminal fragment with NotI and Eco N1,
and ligating the digested amino-terminal fragment into
pCDNA4 myc/his CTPS1-FLAG digested with NotI and Eco
N1. Site-directed mutagenesis was done using QuikChangeTM
(Stratagene) according to the manufacturer’s instructions. All
mutations were verified by sequencing. Of note, Ser-571 was
found to be an isoleucine in the IMAGE clone and wasmutated
back to the wild type serine.
Transfection and Immunoprecipitation of Endogenous and
Recombinant CTPS1—HEK 293 cells were transfected using
LipofectamineTM (Invitrogen) as instructed by the manufac-
turer. Anti-FLAG (Sigma) resin was prepared as recommended
by the manufacturer to remove non-covalently linked antibod-
ies. Approximately 8  106 cells were washed twice with ice-
cold PBS and lysed with 0.5 ml of radioimmune precipitation
(RIPA) buffer without SDS (150 mM NaCl, 9.1 mM Na2HPO4,
1.7 mM NaH2PO4, 1% Nonidet P-40 substitute, and 0.5%
sodium deoxycholate) containing 1 g/ml leupeptin, 10 nM
microcystin, 1 mM Na3VO4, and 250 M phenylmethylsulfonyl
fluoride. Following clarification of lysate by centrifugation, 1
mg of lysate was rotated with 10 l of anti-FLAG resin over-
night at 4 °C. Immunoprecipitation of endogenous CTPS1 was
done by rotating 1 mg of lysate clarified by centrifugation with
10l of anti-CTPS1 antibody overnight at 4 °C. 10l of protein
A-agarose beads (Santa Cruz Biotechnology) was added to
lysate containing anti-CTPS1 antibody and rotated an addi-
tional hour at 4 °C.
CTPS Activity Assay—CTPS1 was immunoprecipitated as
described above. Immunoprecipitates were washed three times
with 0.5 ml of RIPA buffer without SDS containing 5 g/ml
leupeptin and a final wash was done with 1 ml of 1 CTPS
reaction buffer (50mMTricine, pH8.1, 20mMMgCl2, and 5mM
KCl). The volume was adjusted to 40 l with 10 l of 5 reac-
tion buffer and 30 l of double distilled H2O (ddH2O). CTPS1
and 5 substratemix (5mMATP, 0.5mMUTP, 5mMGTP, 100
mM L-glutamine, and 0.625 Ci/ml [14C]UTP or 0.1 Ci/ml
[3H]UTP)were equilibrated to 37 °C. The reactionwas initiated
by adding 10 l of 5 substrate mix to 40 l of CTPS1 in
reaction buffer and stopped after 45 min by adding 10 l of 200
mM EDTA and removing the tube to ice. CTPS1 reactions were
reduced to dryness using a SpeedVac. Dried supernatant pellets
were resuspended in 10 l of ddH2O. 3–4 l of resuspended
pellets and 1 l of 100 mM UTP/CTP/UDP/CDP standards
were spotted onto polyethylimine cellulose plastic-backed
plates (Fisher Scientific) that were prewashed for 10 min with
ddH20, 5 min with 0.65 N HCl, and 1 min with methanol.
Nucleotides were resolved using 0.65 N HCl as the ascending
chromatography buffer. Areas corresponding to UTP, CTP,
UDP, and CDP were visualized with a short wavelength UV
light, and nucleotide areas containing radioactivity were visu-
alized by exposing TLC plate to a phosphorimaging screen
overnight. Areas corresponding to UTP, CTP, UDP, and CDP
were excised and counted using EcoscintTM (Fisher Scientific)
scintillation fluid.
Antibodies and Immunoblotting—Anti-CTPS1 (human) anti-
body was generated by Rockland Immunochemicals using a
carboxyl-terminal peptide (amino acids 578–591, H2N-
CSEITELKFPSINHD-COOH) containing an amino-terminal
cysteine for coupling to peptide affinity column and keyhole
limpet hemocyanin. Anti-CTPS1 antibody was purified from
rabbit serum in a three-step process. First, serum proteins
including immunoglobulins were precipitated at 4 °C by adding
ice-cold saturated (NH4)2SO4 to a final percentage of 50%.
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(NH4)2SO4-precipitated proteins were resuspended in a vol-
ume of PBS equal to the initial volume of serum and dialyzed
overnight at 4 °C against PBS. Second, 2.5 ml of (NH4)2SO4
purified serum protein solution was rotated with 0.5 ml (bead
volume) of protein A that had been equilibrated with 100 mM
Tris, pH 8.0. After washing the protein A column with 100 mM
Tris, pH 8.0, and 10 mM Tris, pH 8.0, bound antibodies were
eluted with 5 ml of 50 mM glycine, pH 3.0. 1-ml fractions were
collected in Eppendorf tubes containing 100 l of 1 M Tris, pH
8.0, to immediately neutralize pH. All fractions were pooled
and dialyzed overnight at 4 °C against PBS. Lastly, antibodies
specific for CTPS1 were separated from nonspecific antibodies
using a peptide affinity column created with the antigenic pep-
tide (H2N-CSEITELKFPSINHD-COOH) and a Sulfolink col-
umn (Pierce Biotechnologies) according to the manufacturer’s
instructions. Eluted anti-CTPS1 antibodies were concentrated
to350l and buffer exchanged to PBSwith 0.05%NaN3 using
4ml of 10-kDaMWCOspin concentrators. 20-l aliquots were
stored at 20 °C for future use.
Immunoblotting for GSK3 and phospho-GSK3 (/, Ser-21/
Ser-9) was done by lysingHEK293 cells with RIPAwithout SDS
and determining the protein concentration in lysate using the
method of Bradford (17). Lysates were prepared for SDS-PAGE
by adding an equal volume of 2 SDS sample buffer (0.5 MTris,
pH 6.8, 4% SDS, 20% glycerol, 10% -mercaptoethanol, 0.002
g/ml bromphenol blue). 10–40 g of protein was separated on
an 8 or 10% discontinuous buffer gel, and proteins were trans-
ferred to polyvinylidene fluoride membrane (Immobilin-P;
Millipore). Membranes were blocked for 1 h at room tempera-
ture or overnight in a cold room with 3% w/v cold fish gelatin
(Sigma) diluted with TBST (10 mM Tris, pH 8.0, 150 mM NaCl,
0.05% Tween 20). Primary antibodies (1:1000 -phospho-
(Ser-9) GSK3 (Cell Signaling) and 1:1000 -GSK3 (Cell Sig-
naling)) were diluted in 1% w/v gelatin in TBST and incubated
with membranes for 1 h at room temperature (-GSK3) or
overnight at 4 °C (-phospho-(Ser-9) GSK3; Cell Signaling).
Membranes were thenwashedwith TBST three times for 5min
each wash and incubated for 1 h with 1:2000 goat anti-rabbit
(Santa Cruz) conjugated to horseradish peroxidase (for
-GSK3) or alkaline phosphatase (for -phospho-(Ser-9)
GSK3). Membranes were washed three times for 5 min each
wash with TBST and visualized using an enhanced chemilumi-
nescent kit (AmershamBiosciences) according to themanufac-
turer’s instructions and exposing membrane to x-ray film or
using a BCIP/NBT kit (5-bromo-4-chloro-3-indolyl phos-
phate/nitro blue tetrazolium) (Promega) to visualize alkaline
phosphatase-conjugated secondary antibody as suggested by
the manufacturer.
GSK3 RNA Interference—3.5  105 HEK 293 cells were
plated onto 60-mm poly-D-lysine-coated plates and incubated
overnight. DMEM containing 10% FBS and penicillin/strepto-
mycin (DMEM  10% FBS  pen./strep.) was removed from
cells, and medium was replaced with DMEM containing 10%
FBS and no antibiotics (DMEM  10% FBS). RNA duplexes
(Dharmacon) were suspended as suggested by the manufac-
turer, and 15 l of 20 M RNA duplex was added to one tube
containing 285l of DMEM 10% FBS andmixed thoroughly.
12 l of Dharmafect 1 was added to a second tube containing
288 l of DMEM  10% FBS and mixed thoroughly. Tubes
containing RNA duplexes and Dharmafect 1 were combined,
mixed thoroughly, and allowed to stand at room temperature
for 20 min. 2400 l of DMEM  10% FBS was added to the
duplex/Dharmafect 1 mixture to give a total volume of 3000 l,
and the entire mixture (3000 l) was added to plates that had
their medium removed. Medium was switched the following
day toDMEM 10% FBS pen./strep. Cellularmanipulations
were done the following day after incubating cells overnight.
In Vitro GSK3 Kinase Reaction—Endogenous CTPS1 or
FLAG-CTPS1 was immunoprecipitated as described before.
Immunoprecipitates were washed one time with 1 ml of 1
GSK3 reaction buffer (20 mM Tris, pH 7.5, at 25 °C and 10 mM
MgCl2) without dithiothreitol and 25 l of complete GSK3
reaction buffer (20 mM Tris, pH 7.5, at 25 °C, 10 mM MgCl2, 10
M ATP, 2 l of [-32P]ATP (10 mCi/ml; PerkinElmer), 5
g/ml leupeptin, 10 nM microcystin, and 5 mM dithiothreitol)
was added to each immunoprecipitate. To each reaction 0.01
units of GSK3-purified enzyme (New England Biolabs) were
added and incubated at 30 °C for 30 min, flicking tubes occa-
sionally to resuspend immunoprecipitates. Reactions were
stopped by removing the supernatant, placing tubes on ice, and
adding 30 l of 1 SDS sample buffer (see “Antibodies and
Immunoblotting” for composition of SDS sample buffer) to
immunoprecipitates.
Calf Intestinal Phosphatase Treatment of CTPS1—Immuno-
precipitated CTPS1 (prepared as described earlier) was washed
three times with 1ml of RIPA buffer without SDS and one time
with 1 ml of 1 CTPS reaction buffer. 10 l of 5 CTPS reac-
tion buffer and 25 l of ddH2O were added to immunoprecipi-
tates, and tubes were placed at 30 °C for phosphatase reaction.
Dephosphorylation was initiated by adding 15 l (1 unit/l) of
calf intestinal phosphatase (CIP; Roch Biochemicals) or 15l of
50% glycerol (control reaction) to tubes containing immuno-
precipitated CTPS1 (50-l total volume). Reactions were
stopped by adding 1 ml of ice-cold 1 CTPS reaction buffer to
dilute reaction components and placing tubes on ice. Immuno-
precipitateswerewashed againwith ice-cold 1CTPS reaction
buffer.
In Vivo Labeling with [32P]Orthophosphate—100-mm tissue
culture plates (Sarstedt Inc.) were coatedwith 0.02mg/ml poly-
D-lysine (Sigma Aldrich) and washed with ddH2O. 7.5  106
HEK 293 cells were plated on poly-D-lysine-coated plates. Cells
were washed one time with 5 ml of phosphate-free DMEM
(phosphate/pyruvate-free DMEM (Invitrogen) supplemented
with sodium pyruvate (Invitrogen), giving a final concentration
of 110mg/liter sodium pyruvate and the same concentration of
penicillin/streptomycin as described earlier). 3 ml of phos-
phate-free DMEM containing 10% dialyzed FBS (Invitrogen)
was added to plates 30 min prior to adding 1 mCi of
[32P]orthophosphate/plate (0.33 mCi/ml; MP Biomedical). In a
typical experiment, cells were labeled for 4 h prior to manipu-
lation. Labeling was stopped by washing plates twice with 5 ml
of ice-cold PBS. Cells were lysed by scraping plates in the pres-
ence of 0.5 ml of no-SDS RIPA buffer. Immunoprecipitations
were done as described above. Immunecomplex proteins were
eluted from beads by boiling for 3 min with Laemmli buffer.
SDS-PAGE/autoradiography was done on eluted proteins.
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Phosphorylation Site Identification by Mass Spectrometry—
HEK 293 cells were labeled and immunecomplexes were sepa-
rated as described above. After separation of eluted proteins by
SDS-PAGE, proteins were transferred to nitrocellulose
(Osmonics; GE Healthcare). Proteins were visualized using
MemCode (Pierce Biotechnologies) according to the manufac-
turer’s instructions. Bands corresponding to CTPS1 were
excised and cut into 1-mm pieces. Membrane pieces were
placed in a siliconized microfuge tube, and MemCode destain-
ing was done as recommended by the manufacturer. After
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membrane pieces were washed three times with ddH2O, they
were incubatedwith 1%w/v polyvinylpyrrolidone suspended in
100 mM acetic acid for at least 1 h at 37 °C. Membrane pieces
were washed four times with ddH2O to ensure residual polyvi-
nylpyrrolidonewas removed.Membrane pieceswere incubated
with 0.5 g of TPCK-modified sequencing grade trypsin (Pro-
mega) in 25 mM ammonium bicarbonate, pH 8.0, overnight at
37 °C. Peptides were collected by removing the trypsin solution
to a clean tube, washing the membrane pieces three times with
ddH2O, and removing each ddH2Owash to the same clean tube
containing the trypsin solution. The volume of collected pep-
tides was reduced to a final volume of10 l using a speed vac.
Recovery of radioactivity from membrane pieces was at least
85% as determined by Cerenkov counting. For separation of
peptides on cellulose TLC plate, peptides were washed at least
three times with ddH2O to remove ammonium bicarbonate.
After the final ddH2O wash, peptides were resuspended in the
first dimension buffer (pH 1.9 buffer, 15% v/v acetic acid, and
5% v/v of 88% formic acid) to give a final volume of 8 l. The
peptideswere spotted in a corner of a 10 10-cmcelluloseTLC
plate, 1.5 cm from the sides of the plate. Peptides were electro-
phoresed in a Hunter thin layer electrophoresis box at 1000 V
for 32 min. After thoroughly drying the TLC plate, peptides
were separated in the second dimension using Scheidtmann
buffer (isobutyric acid-pyridine-acetic acid-butanol-water,
65:5:3:2:29) (18). After exposure of TLC plates to x-ray film or
phosphorimaging plate, radioactive spots indicative of phos-
phopeptides were eluted as described previously (19). Volume
of peptides was decreased to10l using a speed vac. Peptides
were subjected to nano-electrospray ionizationmass spectrom-
etry on anApplied BiosystemsQSTAR pulsarmass spectrom-
eter in positive ion mode. Peptides were sequenced by nano-
electrospray ionization tandem mass spectrometry using
BioAnalyst software.
Data Analysis—Statistical analysis was done using one-way
analysis of variance with a Tukey post-hoc test and a 95% con-
fidence interval.
RESULTS
CTPS1 Is Phosphorylated in Response to Serum Starvation—
Inhibition or activation of protein kinase A or protein kinase C
did not alter the phosphorylation of endogenous humanCTPS1
from [32P]orthophosphate-labeled HEK 293 cells (supplemen-
tal data). Instead, we observed that CTPS1 phosphorylation
increased after incubation overnight in low serum (0.1% FBS).
The average increase in radioactivity associated with endoge-
nous CTPS1 isolated from [32P]orthophosphate-labeled HEK
293 cells in 0.1% FBS was approximately twice that from cells
maintained in 10% FBS. Two-dimensional thin layer chroma-
tography separation of tryptic peptides from endogenous
CTPS1 revealed five major phosphopeptide spots; consistent
with the effects of low serum on CTPS phosphorylation, all five
of these spots increased after serum starvation (Fig. 1A).
Involvement of GSK3 in Phosphorylation of Endogenous
CTPS1—Because we observed that phosphorylation of CTPS1
increased in low serum (0.1%FBS) conditions, kinases known to
be activated under these conditions were investigated. Two
kinases shown to be activated under low serum/nutrient star-
vation conditions are AMP-activated protein kinase and GSK3
(20, 21). Incubation of HEK 293 cells with the AMP-activated
protein kinase inhibitor compound C failed to inhibit the
increase inCTPS1phosphorylation induced by low serum (data
not shown). Analysis of GSK3 demonstrated that the inhibitory
phosphorylation site on GSK3 / (Ser-21, Ser-9 respectively)
was decreased in 0.1% FBS, indicating that GSK3 was more
active when HEK 293 cells were maintained overnight in low
serum (Fig. 1B). To test whether GSK3 was involved in CTPS1
phosphorylation, HEK 293 cells were incubated with the GSK3
inhibitor indirubin-3-monoxime (indirubin) or the vehicle
(Me2SO) overnight in the presence of 10 or 0.1% FBS. The
increase in low serum-induced CTPS1 phosphorylation was
inhibited by indirubin, suggesting GSK3 was a candidate
kinase necessary for the phosphorylation of CTPS1 (Fig. 1C).
Inhibition of GSK3 prevented the low serum-induced phos-
phorylation of CTPS1 in four separate experiments. Shown is a
representative experiment. Furthermore, two-dimensional
phosphopeptide mapping showed that indirubin decreased the
radioactivity of the five phosphopeptide spots equally (Fig. 1C).
To further establish that GSK3 was specifically involved in
low serum-induced CTPS1 phosphorylation, GSK3 protein
expression was specifically reduced by small interfering RNA
(siRNA) (Fig. 1D). GSK3 siRNA almost completely eliminated
GSK3 expression but did not affect GSK3 expression (Fig.
1D). Analysis of CTPS1 phosphorylation in these cells in two
separate experiments demonstrated that low serum-induced
CTPS1 phosphorylation was inhibited in cells transfected with
GSK3 siRNA compared with cells transfected with non-tar-
FIGURE 1. Involvement of GSK3 in phosphorylation of endogenous human CTPS1. A, HEK 293 cells were maintained in 0.1 or 10% FBS overnight and then
labeled with [32P]orthophosphate containing 0.1 or 10% FBS. Lysates were prepared and CTPS1 immunoprecipitated as described under “Experimental
Procedures.” Immunoprecipitated CTPS1 was separated by SDS-PAGE, transferred to nitrocellulose, and exposed to x-ray film. Autoradiograph and two-
dimensional TLC separation of tryptic peptides are representative of four experiments. Total CTPS1 was visualized by MemCode staining the nitrocellulose
membrane. -Fold change bar graph uses data from four experiments (n  4). Error bars represent S.D. B, to determine the status of GSK3 activation, serine 9
phosphorylation of GSK3 was assessed by immunoblotting lysates from [32P]orthophosphate-labeled HEK 293 cells maintained overnight in 10 or 0.1% FBS.
Lysates were prepared as described under “Experimental Procedures.” Student paired t tests were used to determine significance. C, HEK 293 cells maintained
overnight in 10 or 0.1% FBS in the presence of vehicle Me2SO (DMSO) or 10 M indirubin-3-monoxime were [
32P]orthophosphate-labeled as described under
“Experimental Procedures.” Cells were lysed, CTPS1-immunoprecipitated, and visualized as in Fig. 1A. Radioactivity associated with CTPS1 was determined by
excising the corresponding CTPS1 band, Cerenkov counting radioactivity, and adjusting the counts/min (CPM) for protein amount as described under
“Experimental Procedures.” CTPS1 bands were trypsin-digested and two-dimensional thin layer chromatography was performed as described under “Exper-
imental Procedures.” Shown is an experiment representative of four separate experiments. D, HEK 293 cells were transfected with the indicated SmartPool RNA
duplexes from Dharmacon as described under “Experimental Procedures.” Two days following transfection of RNA duplexes, medium was switched to 0.1%
FBS overnight and cells were labeled the following day with [32P]orthophosphate. CTPS1 was immunoprecipitated, separated, and visualized as described in
Fig. 1C. Two-dimensional thin layer chromatography was also performed as described in Fig. 1C. Reduction in GSK3 protein expression was assessed by
immunoblotting with an antibody that recognizes total GSK3 and GSK3. Results are representative of two separate experiments (n  2).
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geting siRNA (Fig. 1D). Although
much of the low serum-induced
CTPS1 phosphorylation was inhib-
ited byGSK3 siRNA, the reduction
was not as significant as that
observed after indirubin treatment
(Fig. 1C), suggesting that GSK3
may also contribute to the phosphor-
ylation of CTPS1.
Identification of Ser-574 and Ser-
575 as Phosphorylation Sites in
Human CTPS1—To identify the
amino acids phosphorylated in
endogenous CTPS1, HEK 293 cells
were labeled with [32P]orthophos-
phate and CTPS1 was isolated by
immunoprecipitation. Tryptic pep-
tides from endogenous CTPS1 were
separated by two-dimensional TLC;
the five phosphopeptide spots rou-
tinely observed were scraped and
the peptides eluted and analyzed by
nano-electrospray ionization tan-
dem mass spectrometry. Spot 3 was
identified as a carboxyl-terminal
tryptic peptide (SGSSS*PDSEIT-
ELK; the asterisk denotes phosphor-
ylation) containing a phosphoryla-
tion on serine 575 (Fig. 2A). Spots 1
and 5 were identified as the same
peptide isolated but the tandem
mass spectrometry data were con-
sistent with a doubly phosphoryla-
ted peptide (SGSS*S*PDSEITELK),
Ser-574 and Ser-575 (Fig. 2A). The
phosphopeptides were not identi-
fied from spots 2 and 4 possibly
because the abundance of the phos-
phopeptide was too low, the ioniza-
tion of these peptides was poor, or
other peptides in the sample caused
ion suppression. Analysis of the
S574A mutant showed decreased
intensity of spot 1 (Fig. 2B), substan-
tiating the identification of this
spot as a tryptic peptide contain-
ing phosphorylated Ser-574 and
Ser-575. The S575Amutant showed
decreased intensity of all the spots
except for spot 3, which was barely
detectable, suggesting that Ser-575
was a major phosphorylation site
and/or that it was required to
“prime” for additional phosphoryla-
tions (Fig. 2B). Mutation of Ser-574,
Ser-575, or both Ser-574/Ser-575 to
alanine (S574A, S575A, S574A/
S575A) significantly decreased the
FIGURE 2. Identification of Ser-574 and Ser-575 as phosphorylation sites in human CTPS1 and involvement
of Ser-574 and Ser-575 in GSK3 phosphorylation of CTPS1. A, HEK 293 cells were labeled with [32P]orthophos-
phate as described under “Experimental Procedures,” and CTPS1 was immunoprecipitated and visualized as
described in Fig. 1C. Trypsinized endogenous CTPS1 peptides were subjected to two-dimensional thin layer chro-
matography as described previously. Radioactive spots observed on autoradiograph from TLC plates were scraped.
Phosphopeptides were eluted from TLC plate backing and subjected to nano-electrospray ionization tandem mass
spectrometry for identification as described under “Experimental Procedures.” B, wild type (WT) FLAG-CTPS1 and
indicated FLAG-CTPS1 phosphorylation site mutants were immunoprecipitated using anti-FLAG resin from trans-
fected HEK 293 cells labeled with [32P]orthophosphate and separated by SDS-PAGE. Following transfer to nitrocel-
lulose, bands corresponding to FLAG-CTPS1 were excised and radioactivity was counted using Cerenkov counting.
Peptides eluted from trypsinized FLAG-CTPS1 WT and phosphorylation site mutants were separated using two-
dimensional thin layer chromatography as described under “Experimental Procedures.” Shown is an experiment
representative of three separate experiments (n  3). C, WT FLAG-CTPS1 or FLAG-CTPS1 phosphorylation site
mutants expressed in HEK 293 cells were immunoprecipitated using anti-FLAG resin as described under “Experi-
mental Procedures.” Endogenous CTPS1 was immunoprecipitated as detailed under “Experimental Procedures.”
Endogenous CTPS1 and immunoprecipitated FLAG-CTPS1 were used as substrates in an in vitro GSK3 kinase
reaction as detailed under “Experimental Procedures.” Following the in vitro GSK3 kinase reaction, endogenous
CTPS1 and indicated FLAG-CTPS1 proteins were separated by SDS-PAGE, transferred to nitrocellulose, and visual-
ized by autoradiography. Radioactivity associated with CTPS1 was determined as in Fig. 1C. Endogenous CTPS1 and
FLAG-CTPS1 proteins were trypsin-digested, and tryptic peptides were subjected to separation by two-dimensional
thin layer chromatography as described under “Experimental Procedures.”
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amount of radioactivity associated with CTPS1 compared with
wild type (WT) CTPS1 (Fig. 2B). Mutation of both Ser-574 and
Ser-575 to alanines almost completely eliminated the radioac-
tivity associated with CTPS1, indicating that Ser-574 and Ser-
575 are two major phosphorylation sites in CTPS1 (Fig. 2B).
Involvement of Ser-574 and Ser-575 in GSK3 Phosphoryla-
tion of CTPS1—To determine whether GSK3 could phos-
phorylate Ser-574 and/or Ser-575 directly, CTPS1 or the indi-
cated phosphorylation site mutants were immunoprecipitated
and used as substrates in an in vitro kinase reactionwithGSK3
(Fig. 2C). Both endogenous and transfected CTPS1 were found
to be substrates for GSK3, whereas by contrast the S574A,
S575A, and the S574A/S575A mutants all showed greatly
reduced phosphorylation by GSK3. These data showed the
ability of GSK3 to phosphorylate CTPS1 and indicated that
Ser-574 and, to a greater extent, Ser-575 were involved in the
direct phosphorylation of CTPS1 by GSK3 (Fig. 2C). Addi-
tionally, these phosphopeptides were separated by two-dimen-
sional TLC to generate phosphopeptide maps and the pattern
of spots compared with the pattern observed from CTPS1
phosphorylated in intact cells (compare phosphopeptide maps
from Fig. 2A to phosphopeptides maps from Fig. 2C). These
data strongly suggested that GSK3 was directly phosphor-
ylating CTPS1 on sites similar to those observed in vivo.
Identification of Ser-571 as a Phosphorylation Site in Human
CTPS1—GSK3 is a hierarchal kinase that requires prior phos-
phorylation of a serine/threonine (S/T) at a position n4 from
the GSK3 phosphorylation site (GSK3 consensus sequence,
S/T-XXX(S/T-Phospho), where X is any amino acid) (22). The
large decrease in phosphorylation observed with the mutation
S575A, both in intact cells and in vitro with GSK3, implicates
Ser-575 as a critical residue involved in GSK3 phosphorylation
of CTPS1. However, whether Ser-575 is serving as the actual
GSK3 phosphorylation site or the priming site for GSK3 phos-
phorylation of Ser-571 could not be determined from the
results in Fig. 2. To determine whether the negative charge of
the glutamate at residue 579 (Glu-579) was serving as a phos-
phomimetic residue priming for GSK3 phosphorylation of Ser-
575, this glutamatewasmutated to alanine (E579A). Analysis of
the E579A mutant in intact HEK 293 cells showed that muta-
tion of this residue did not affect phosphorylation of CTPS1,
demonstrating that Glu-579 does not prime for GSK3 phos-
phorylation of Ser-575 in intact cells (data not shown). Another
possibility was that phosphorylation of Ser-575 could prime for
GSK3 phosphorylation of Ser-571. Interestingly, the CTPS1
clone we received from the IMAGE consortium contained a
mutation of Ser-571 to an isoleucine (S571I). To address
whether Ser-571 was a phosphorylation site in CTPS1 in intact
cells, the S571I mutation was expressed in HEK 293 cells
labeled with [32P]orthophosphate. Following isolation by anti-
FLAG immunoprecipitation, the CTPS1 S571I mutant had
substantially less radioactivity associatedwith it comparedwith
WT CTPS1-FLAG, indicating that Ser-571 was required for
CTPS1 phosphorylation (Fig. 3A). The combined mutation of
Ser-575 and Ser-574/Ser-575 to alanine with S571I decreased
the radioactivity associated with CTPS1, suggesting that Ser-
575 was another major site labeled under these conditions (Fig.
3A). Two-dimensional TLC revealed that when Ser-571 was
mutated to an isoleucine, themajority of radioactive spots were
diminished, with the exception of one prominent spot (Fig. 3A).
This phosphopeptide spot did not disappear when Ser-574 was
mutated to alanine in combination with S571I but was absent
from the S571I/S575A double mutant, suggesting that the
phosphopeptide that gives rise to this spot is dependent on
Ser-575 being phosphorylated (Fig. 3A). Because serine 571 is
mutated to a more hydrophobic residue (isoleucine), phos-
phorylated peptides containing this isoleucine would migrate
farther in the second dimension of the two-dimensional phos-
phopeptide map but maintain approximately the same migra-
tion distance in the first dimension. This suggests that the
prominent radioactive spot observed when Ser-571 was
mutated to an isoleucine correspondsmost likely to spot 2 or 3.
Consistent with this, spot 3 was identified earlier as the same
tryptic peptide containing unphosphorylated Ser-571 and sin-
gly phosphorylated Ser-575 (See Fig. 2A).
Involvement of Ser-571 in GSK3 Phosphorylation of CTPS1—
To determine whether Ser-571 was a substrate for direct phos-
phorylation by GSK3, WT, S571I, S571I/S574A, S571I/S575A,
and S571I/S574A/S575A were used as substrates in an in vitro
kinase reaction withGSK3. Incubation withGSK3 increased
the phosphorylation of WT CTPS1 whereas the phosphoryla-
tion of S571I was significantly lower, demonstrating that Ser-
571 was indeed a phosphorylation site for GSK3 (Fig. 3B).
Analysis of the S571I/S574A phosphorylation site mutant did
not show altered incorporation of phosphate compared with
S571I alone, but analysis of the S571I/S575A mutant showed
slightly elevated amounts of phosphate incorporated into CTPS1
compared with S571I, suggesting that without the ability to
phosphorylate Ser-571 or Ser-575 in vitro, GSK3 may phos-
phorylate an alternative site, albeit to a much lesser extent.
Analysis of the triple mutant S571I/S574A/S575A showed a
slight decrease in the amount of phosphate incorporated into
CTPS1 compared with S571I/S575A, suggesting that Ser-574
may serve as a minor secondary site for GSK3 phosphoryla-
tion in vitro (Fig. 3B). Separation of phosphorylated peptides
from the in vitro GSK3 kinase reaction by two-dimensional
TLC demonstrated that spots 1 and 5 were the most intense
(see arrow in Fig. 3B). Althoughwe previously found the doubly
phosphorylated (Ser-574 and Ser-575) peptide in these two
spots, this does not preclude the co-migration of other phos-
phorylated peptides, in particular phosphorylated peptides that
are not as easily detected using mass spectrometry, such as a
large multiply phosphorylated peptide similar to the one that
would be generated if Ser-571 were phosphorylated. As expected,
mutation of Ser-571 to isoleucine (S571I) abolished the appear-
anceof this spot (seearrow inFig. 3B), demonstrating that this spot
containsphosphorylatedSer-571and thatSer-571 is themajor site
in CTPS1 forGSK3. Because the phosphorylation of CTPS1was
performed in vitro, only sites phosphorylated by GSK3 would
incorporate radioactivity; other residues phosphorylated prior to
the in vitro kinase reaction may still be phosphorylated but not
labeledwith radioactivity. BecauseGSK3 requires priming phos-
phorylation, this spot (Fig. 3B, arrow) contains a peptide with at
least two phosphorylated residues, Ser-571 and Ser-575 (Fig. 3B).
Further mutation of Ser-574, Ser-575, and both Ser-574/Ser-575
to alanine combined with S571I did not change the results
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observed with S571I alone, again
demonstrating that Ser-571 was the
major target of GSK3 in vitro.
The Effect of GSK3 Inhibition and
Serum on CTPS1 Activity—Most
GSK3 substrates are negatively reg-
ulatedbyGSK3phosphorylation (23–
33). To examine whether CTPS1 was
regulated by GSK3 phosphorylation,
endogenous CTPS1 was isolated by
immunoprecipitation from HEK 293
cells maintained in 10% FBS, 0.1%
FBS, or 0.1% FBS with the GSK3
inhibitor indirubin, and the amount
of CTPS1 activity was assayed. Incu-
bation of cells with low serum
decreasedCTPS1 activity compared
with cells incubated with 10% FBS
(Fig. 4A) and paralleled the effect of
these treatments on CTPS1 phos-
phorylation. Incubation of cells in
low serum in the presence of the
GSK3 inhibitor indirubin preserved
CTPS1 activity (Fig. 4A), consistent
withGSK3phosphorylation inhibit-
ing the activity of CTPS1.
The Effect of Phosphatase Treat-
ment on CTPS1 Activity—To fur-
ther examine the effect of phosphor-
ylation on CTPS1 activity, CTPS1
was isolated from low serum-incu-
batedHEK293 cells by immunopre-
cipitation, treated for 7.5, 15, or 30
min with calf intestinal phosphatase
(CIP), and CTPS1 activity was
measured (Fig. 4B). CTPS1 was sig-
nificantly dephosphorylated after
15 min of incubation with CIP as
seen by phosphorimaging of total
isolated CTPS1 and in the two-di-
mensional phosphopeptide map
(Fig. 4B). The decrease in spot
intensity of multiple spots in the
two-dimensional phosphopeptide
maps following phosphatase treat-
ment suggests that multiple resi-
dues, including Ser-571, Ser-574,
and Ser-575, are being dephosphor-
ylated. CTPS1 activity increased
with the time of incubation with
CIP, demonstrating that CTPS1was
more active following dephosphor-
ylation of the enzyme (Fig. 4B).
DISCUSSION
Although phosphorylation regu-
lation of yeast and human CTPS1
expressed in yeast has been investi-
FIGURE 3. Identification of Ser-571 as a phosphorylation site in human CTPS1 and involvement of Ser-
571 in GSK3 phosphorylation of CTPS1. A, as in Fig. 1B, HEK 293 cells were transfected with the indicated
DNA. Following [32P]orthophosphate labeling of cells, radiolabeled CTPS1 protein was immunoprecipitated,
separated by SDS-PAGE, transferred to nitrocellulose, and visualized either by autoradiography or phosphor-
imaging analysis. Tryptic peptides were separated by two-dimensional thin layer chromatography as described
under “Experimental Procedures.” B, as in Fig. 2C, WT FLAG-CTPS1 and indicated FLAG-tagged CTPS1 phos-
phorylation site mutants were used as substrates in an in vitro GSK3 kinase reaction. In vitro GSK3 phospho-
rylation of WT and CTPS1 phosphorylation site mutants were analyzed by autoradiography, Cerenkov count-
ing, and two-dimensional thin layer chromatography as described in Fig. 2C. Unlike in Fig. 2C, only a quarter of
the isolated peptides were loaded onto the TLC plate to avoid overloading the plate with radioactivity.
* indicates a nonspecific immunoprecipitated protein observed in the autoradiograph migrating just below
FLAG-CTPS1. Arrow indicates FLAG-CTPS1.
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gated, this is the first investigation of the phosphorylation reg-
ulation of human CTPS1 in human cells. Unlike yeast CTPS1,
endogenous human CTPS1 was not phosphorylated by protein
kinase A or protein kinase C under the conditions examined in
this study. This is consistent with many of the protein kinase A
and protein kinase C sites found in yeast CTPS1 not being con-
served in human CTPS1 (supplemental data). Instead, our
results point to novel and unexpected phosphorylation of the
carboxyl terminus of human CTPS1. None of these sites in the
carboxyl terminus of human CTPS1 are consensus protein
kinase A or protein kinase C sites, consistent with our results.
Sequence alignment of the carboxyl termini from various orga-
nisms shows how conserved many of the phosphorylation sites
are among mammals, but not in other eukaryotes (e.g. fly,
worm, yeast) (Fig. 5). The observation that the sequence con-
servation varies between mammals and Drosophila melano-
gaster and Caenorhabditis elegans does not preclude that D.
melanogaster and C. elegans are regulated by phosphorylation
on their carboxyl terminus but does suggest that the regulation
of mammalian CTPS1 by phosphorylation may be different in
these organisms. The difference between the carboxyl terminus
from yeast and humanCTPS1 suggests that humanCTPS1, and
perhaps nucleotide metabolism, is regulated differently in
humans than in yeast. Ser-571 is highly conserved in all the
mammalian sequences examined and is even conserved in
CTPS2, indicating the potential importance of this residue
in the phosphorylation control of mammalian CTPS. In human
and mouse CTPS, Ser-575 is found only in CTPS1 and not in
CTPS2 whereas in both CTPS1 and CTPS2 from other mam-
mals position 575 is conserved. The ability of position 575 to be
phosphorylated in both CTPS1 and CTPS2 from other mam-
malsmay indicate amore redundant role forCTPS1 andCTPS2
in these organisms, whereas the ability for 575 to be phosphor-
ylated only in human and mouse CTPS1, but not CTPS2, sug-
gests different roles forCTPS1 andCTPS2 in humans andmice.
Multiple lines of evidence point to the role of GSK3 to phos-
phorylate and regulate CTPS1. Inhibition of GSK3 with the
inhibitor indirubin and siRNA revealed thatGSK3was involved
in the low serum-induced phosphorylation of endogenous
humanCTPS1.Mutationof Ser-575 toalanine inhibitedmuchof
the radioactivity associated with CTPS1, and Ser-575 was investi-
gated as a direct GSK3 phosphorylation site by mutating the
potential priming site, Glu-579, to alanine (E579A). Because the
E579Amutant failed to alterCTPS1phosphorylation, Ser-575was
investigatedasaprimingsite forphosphorylationofSer-571.From
these studies it was concluded that Ser-571 was the major site for
GSK3 phosphorylation in vitro (Fig. 5). Interestingly, the CTPS1
clone we received from the IMAGE consortium, derived from a
retinitis pigmentosa cell line, contained a naturally occurring
mutation of Ser-571 to isoleucine (S571I), which suggests that
phosphorylation of Ser-571 may play a role in diseases such as
retinitis pigmentosa. The kinase responsible for phosphorylation
of Ser-575 was not identified despite investigation of a variety of
well knownproline-directedkinases (e.g.ERK, c-Junamino-termi-
nal kinase (JNK), p38, and cyclin-dependent kinases).3
Large scale analyses of the phosphoproteome identified
numerous phosphorylation sites in the carboxyl terminus of
CTPS1 (Ser-562, Thr-566, Tyr-567, Ser-568, Ser-571, Ser-573,
Ser-574, Ser-575, Ser-578, and Thr-581) (34). Our studies con-
firmed the phosphorylation of Ser-571, Ser-574, and Ser-575.
The fact that the other sites were not detected in our analysis
suggests that the other sites may be minor phosphory-
lation sites orwere not labeled under the conditions used in this
study. Interestingly, tyrosine phosphorylation was found on
CTPS1 using an anti-phosphotyrosine antibody but did not
require Ser-571 to be phosphorylated (data not shown). Phos-
phoamino acid analysis of CTPS1 also paralleled the results of
the large scale phosphoproteome analysis, demonstrating that
serine was the most highly phosphorylated amino acid, fol-
lowed by threonine, and that phosphorylation of tyrosine was
below the limits of detection by radioactivity (data not shown).
The observation that multiple phosphorylation sites are clus-
tered in the carboxyl terminus of mammalian CTPS1 suggests
3 M. J. Higgins and L. M. Graves, unpublished data.
FIGURE 4. Effect of serum, indirubin, and phosphatase treatment on
CTPS1 activity. A, endogenous CTPS1 was immunoprecipitated from HEK
293 cells maintained overnight in 10% FBS, 0.1% FBS or 0.1% FBS with 10 M
indirubin (indirubin-3-monoxime). CTPS1 activity was determined as
described under “Experimental Procedures.” Statistical analysis was done
using one-way analysis of variance (95% confidence interval) and a Tukey
post hoc test. p  0.05 was considered significant and designated by an aster-
isk. B, endogenous CTPS1 was immunoprecipitated from HEK 293 cells main-
tained overnight in 0.1% FBS. Immunoprecipitated endogenous CTPS1 was
treated for the indicated times with 15 units of calf intestinal alkaline phos-
phatase (CIP) or equivalent volume of CIP suspension buffer (50% glycerol) as
a control for 30 min as detailed under “Experimental Procedures.” Following
CIP treatment, CTPS1 was washed with 1 CTPS reaction buffer and CTPS
activity was assayed as described under “Experimental Procedures.” Statisti-
cal analysis was done using one-way analysis of variance (95% confidence inter-
val) and a Tukey posthoc test. *, p  0.05; **, p  0.01; and ***, p  0.001 were
considered significant. Endogenous CTPS1 from [32P]orthophosphate-labeled
HEK 293 cells maintained in 0.1% FBS overnight was immunoprecipitated and
treated with CIP or equivalent amount of 50% glycerol as a control for 15 min.
Radioactivity associated with CTPS1 and control-treated endogenous CTPS1 was
visualized by phosphorimaging. CIP and control-treated CTPS1 was also ana-
lyzed by two-dimensional thin layer chromatography as previously described in
Fig. 1C and in detail under “Experimental Procedures.” Error bars represent S.D.
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that multiple kinases may be involved in phosphorylation reg-
ulation of CTPS1, including other hierarchal kinases such as
casein kinase 1. Our data demonstrate a unique regulation of
CTPS1 activity by GSK3 phosphorylation.
The crystal structures of bacterial CTPS have identified con-
served amino acids that are proposed to be necessary for catal-
ysis, dimerization, and tetramerization (35, 36). However, the
carboxyl-terminal region containing Ser-571, Ser-574, and Ser-
575 is not present in these three-dimensional structures, mak-
ing it difficult to predict exactly how phosphorylation of the
carboxyl terminus affects CTPS activity. Analysis of the hydro-
phobicity/hydrophilicity of human CTPS1 using the Kyte-
Doolittle hydrophobicity scale indicates that the carboxyl ter-
minus is hydrophilic and is most likely solvent-exposed,
possibly allowing for interaction with proteins that affect CTPS
activity. Phosphorylation of yeast CTPS1 affects activity
through altering the tetramerization of CTPS1 (37), providing a
precedent for how phosphorylation of human CTPS1 may reg-
ulate CTPS activity. Phosphorylation of human CTPS1 on the
carboxyl terminus could directly influence tetramerization (e.g.
negative charges of phosphate could cause domains to shift,
allowing for tetramerization) or phosphorylation of the car-
boxyl terminus could affect tetramerization indirectly, for
instance by recruiting a protein (or displacing a protein) that
alters tetramerization. Both 14-3-3 and WW domain-contain-
ing proteins such as Pin1 interact specifically with phosphory-
lated residues and could mediate changes in CTPS1 activity.
Interestingly, a large scale analysis of HeLa cell proteins that
interact with 14-3-3 identified CTPS as an interacting protein
(38).
GSK3was originally identified as the third kinase responsible
for the phosphorylation of glycogen synthase, which decreased
glycogen synthase activity (39, 40). Since this seminal discovery,
multiple substrates and cellular roles of GSK3 have been eluci-
dated. Many GSK3 substrates identified are involved in metab-
olism (e.g. glycogen synthase, acetyl-CoA carboxylase, insulin
receptor substrate, pyruvate dehydrogenase), demonstrating a
prominent role forGSK3 in regulatingmetabolism (reviewed in
Ref. 41). The decrease in CTPS1 activity by GSK3 is consistent
with GSK3 negatively regulating the function of other known
GSK3 substrates (e.g. glycogen synthase, -catenin, pyruvate
dehydrogenase) and supporting the role of GSK3 phosphory-
lation as catalyzing inhibitory events. Interestingly, the car-
boxyl terminus of mammalian CTP:phosphocholine cytidylyl
transferase (CCT, EC: 2.7.7.15), which is the rate-limiting
enzyme in phosphatidylcholine biosynthesis and the next bio-
synthetic step in phospholipid metabolism, is phosphorylated
onmultiple sites like CTPS1 (42, 43).Moreover, CCT activity is
decreased by phosphorylation (42, 43). Multiple phosphoryla-
tion sites in the carboxyl terminus of CCT are GSK3 consensus
sites, suggesting that phosphatidylcholine, and possibly phos-
pholipid synthesis in general, may be regulated by GSK3 phos-
phorylation of rate-limiting enzymes such as CCT and CTPS1.
In yeast Carman and co-workers demonstrated the critical role
of CTP and CTPS phosphorylation in regulating phospholipid
synthesis (14, 44, 45). Hatch and Mclarty (46) showed CTPS
activity is critical for phospholipid synthesis in mammalian
cells, supporting the notion that CTP synthesis and phospho-
lipid synthesis could be coordinately regulated.
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